November 25, 2025 a 01:00 pm
INCY: Fundamental Ratio Analysis - Incyte Corporation
Incyte Corporation continues to show strong potential amid its robust pipeline of proprietary therapeutics. The company's sustained R&D efforts, combined with strategic collaborations, reflect positively on its long-term growth prospects. However, investors should be mindful of the inherent risks associated with the biotech sector.
Fundamental Rating
Incyte Corporation's fundamental rating suggests a solid standing with strength in return on equity and assets, although there could be improvements in its debt management and valuation metrics.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 3 | |
| Price to Earnings | 2 | |
| Price to Book | 2 |
Historical Rating
The historical data indicates consistent performance in key financial metrics with no major fluctuations over the specified period.
| Date | Overall Score | DCF | ROE | ROA | Debt-Equity | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|---|---|
| 2025-11-24 | 4 | 4 | 5 | 5 | 3 | 2 | 2 |
| Earlier | 0 | 4 | 5 | 5 | 3 | 2 | 2 |
Analyst Price Targets
Analysts have set varied price targets for Incyte Corporation, indicating optimistic growth potential within a wide price range.
| High | Low | Median | Consensus |
|---|---|---|---|
| 115 | 68 | 95 | 93.17 |
Analyst Sentiment
The sentiment towards INCY stock displays a strong inclination towards 'Buy', with a few 'Hold' and minimal 'Sell' recommendations.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 23 | |
| Hold | 18 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Incyte Corporation presents potential investment opportunities owing to its innovative therapeutic developments and sound financial metrics. As a prominent player in the biopharmaceutical space, the company benefits from strategic collaborations and a promising product pipeline, offering growth prospects. However, the inherent risks of drug development failures and market volatility are factors investors should consider. The already high involvement by analysts favoring a 'Buy' stance could also indicate limited price discovery, urging caution. Overall, Incyte remains a noteworthy consideration for investors with an appetite for the biotech sector's risks and rewards.